SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Batista P.) srt2:(2003-2004)"

Sökning: WFRF:(Batista P.) > (2003-2004)

  • Resultat 1-3 av 3
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Wernemyr, Claes, 1949, et al. (författare)
  • Users’ experience of a virtual reality architectural model compared with users’ experience of the completed building
  • 2003
  • Ingår i: Proceedings of the 1st international conference on advanced research in virtual and rapid prototyping. ; , s. 363-370, s. 363-370
  • Konferensbidrag (refereegranskat)abstract
    • This research investigated how the employees of a company experienced a VR-model of an office building that was to be their future work place and how that VR-experience com¬pared with the employees’ experience of the completed building. About two years after the VR-showings the building was completed and the staff had moved into the building. The results for the employees who saw the VR-presentation for the Semantic environment de¬scrip¬tion scale (SMB) comparing the experiences of the VR-model with the experiences of the completed real building suggested that the experience of the VR-model gave a fairly accurate representation of the experience of the real building However, the reactions to the VR-model were more appreciative after the VR-show as compared with when the VR-model was compared with the real building.
  •  
2.
  • Batista, N, et al. (författare)
  • Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer.
  • 2004
  • Ingår i: Br J Cancer. - 0007-0920. ; 90:9, s. 1740-6
  • Tidskriftsartikel (refereegranskat)abstract
    • The addition of oral capecitabine to docetaxel improves response rate, time to progression (TTP) and overall survival in anthracycline-pretreated metastatic breast cancer (MBC). This phase II study evaluates the efficacy and safety of a 21-day cycle of oral capecitabine (1000 mg m(-2) twice daily, days 1-14) plus i.v. paclitaxel (175 mg m(-2), day 1) in anthracycline-pretreated advanced/MBC. In all, 73 patients were enrolled at 13 Swedish and Spanish centres. The objective response rate was 52% (95% confidence interval (CI): 40-63%) in the intent-to-treat population, including complete responses in 11%. Disease was stabilised in a further 29%. The median time to disease progression (TTP) was 8.1 months and the median overall survival was 16.5 months. The combination was generally well tolerated with a predictable safety profile. The most common treatment-related nonhaematological adverse events were hand-foot syndrome (42%), alopecia (30%) and diarrhoea (26%). The only treatment-related Grade 3/4 adverse events occurring in >5% of patients were alopecia (22%) and hand-foot syndrome (11%). Grade 3/4 neutropenia and lymphocytopenia were reported in 12 and 14% of patients, respectively. Capecitabine plus paclitaxel is highly active with a favourable safety profile in anthracycline-pretreated MBC.
  •  
3.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-3 av 3

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy